CytoMed Therapeutics Files 6-K for Period Ending 06/30/2025
Ticker: GDTC · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1873093
| Field | Detail |
|---|---|
| Company | Cytomed Therapeutics LTD (GDTC) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 6-K, foreign-private-issuer
TL;DR
CytoMed Therapeutics (CTMD) filed its Q2 2025 6-K. Check financials.
AI Summary
CytoMed Therapeutics Limited, formerly CytoMed Therapeutics Pte. Ltd., filed a Form 6-K report for the financial period ended June 30, 2025. The company, incorporated in Singapore and operating in Pharmaceutical Preparations, is located at 1 Commonwealth Lane, Singapore. This filing is made under the Securities Exchange Act of 1934.
Why It Matters
This filing provides an update on CytoMed Therapeutics' financial reporting for the second quarter of 2025, which is crucial for investors to assess the company's performance and financial health.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial disclosures that would inherently increase risk.
Key Numbers
- 06/30/2025 — Financial Period End (The report covers the period ending on this date.)
Key Players & Entities
- CytoMed Therapeutics Limited (company) — Registrant
- CytoMed Therapeutics Pte. Ltd. (company) — Former company name
- June 30, 2025 (date) — Financial period end date
- 1 Commonwealth Lane, Singapore 149544 (address) — Principal Executive Office
- 001-41677 (filing_number) — Commission File Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the financial period ended June 30, 2025.
What was CytoMed Therapeutics Limited's former name?
CytoMed Therapeutics Limited's former name was CytoMed Therapeutics Pte. Ltd., with a date of name change on July 16, 2021.
Where is CytoMed Therapeutics Limited's principal executive office located?
The principal executive office is located at 1 Commonwealth Lane #08-22, Singapore 149544.
What is the Commission File Number for CytoMed Therapeutics Limited?
The Commission File Number is 001-41677.
Does CytoMed Therapeutics file annual reports under Form 20-F?
The filing indicates 'Yes' for the check mark indicating whether the registrant files or will file annual reports under cover of Form 20-F.
Filing Stats: 341 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2025-09-30 07:00:42
Filing Documents
- form6-k.htm (6-K) — 20KB
- ex99-1.htm (EX-99.1) — 505KB
- ex99-2.htm (EX-99.2) — 33KB
- 0001493152-25-016169.txt ( ) — 559KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited By: /s/ CHOO Chee Kong Name: CHOO Chee Kong Date: September 30, 2025 Title: Director and Chairman